Syros to present new data on lead drug candidates at upcoming AACR meeting
Syros Pharmaceuticals announced that the company will present new data on three of its clinical and preclinical programs at the American Association for Cancer Research Annual Meeting taking place April 1-5 in Washington, D.C. The new data will be highlighted in five presentations: Three on SY-1425, an oral first-in-class selective retinoic acid receptor alpha agonist that is currently in a Phase 2 clinical trial in defined subsets of acute myeloid leukemia and myelodysplastic syndrome patients with a RARA biomarker; One on SY-1365, a first-in-class selective cyclin-dependent kinase 7 inhibitor that is on track to begin a Phase 1 trial in the first half of this year in transcriptionally driven solid tumors; and one on its cyclin-dependent kinase 12/13 inhibitor program. "The presentations at AACR showcase both the productivity of Syros' gene control platform and the potential of our first-in-class programs to provide a meaningful benefit for patients with a range of aggressive cancers both as single agents and in combination with other targeted therapies," said Nancy Simonian, M.D., Chief Executive Officer of Syros. "Our platform is the first focused solely on the regulatory genome to systematically identify and target disease-causing alterations in gene expression with the aim of treating diseases that have eluded other genomic-based approaches. In just three years since our inception, this pioneering approach has led to a robust and growing pipeline, with our lead program in a Phase 2 clinical trial, our second program poised to start clinical development in the first half of this year and multiple other programs in preclinical development. We are excited to be presenting data from multiple programs across all stages of our pipeline."